Bedrijfsoverzicht
Pacira BioSciences, Inc. is a healthcare entity focused on the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions for medical practitioners in the United States. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which denotes a focus on specialized pharmaceutical formulations rather than mass-market generic drugs. As of the latest reporting, Pacira BioSciences, Inc. holds a market capitalization of $1.02 billion and generates annual revenue of $726.41 million, employing a workforce of 825 individuals. These financial figures indicate that the company has established a significant mid-cap presence with substantial revenue generation capabilities, suggesting a mature operational scale that supports its specialized product portfolio in the pain management landscape.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $726.41 million alongside a net income of $7.03 million and an EBITDA of $124.33 million. The substantial gap between the total revenue and the relatively modest net income reveals a cost structure where operating expenses or non-operating costs consume a significant portion of top-line earnings before reaching the bottom line. Pacira BioSciences, Inc. demonstrates robust financial flexibility with a free cash flow of $108.56 million, indicating that the business generates sufficient cash to cover capital expenditures and potentially fund future R&D initiatives without immediate reliance on external financing. The margin profile presents a mixed picture with a gross margin of 63.2%, reflecting efficient production or high-value specialty formulations, contrasted by an operating margin of -1.2% and a profit margin of 1.0%. The negative operating margin suggests that while product margins are healthy, overhead costs, R&D, or selling expenses are currently eroding operating profitability. On the balance sheet, the company holds $238.42 million in cash against total debt of $418.20 million, resulting in a debt-to-equity ratio of 60.34, which indicates a leveraged position where debt obligations exceed available cash reserves. Despite the leverage, the current ratio stands at 4.54, a metric that indicates strong short-term liquidity and a substantial ability to meet current liabilities with existing current assets. Return on Equity and Return on Assets stand at 1.0% and 1.5% respectively, metrics that reveal management effectiveness is currently low, generating minimal returns relative to the equity invested and total asset base.
Waarderingsbeoordeling
Pacira BioSciences, Inc. trades with a trailing twelve-month P/E ratio of 148.69 and a forward P/E of 6.81. The stark difference between these two ratios implies that the market expects a dramatic improvement in earnings trajectory in the future to align the forward valuation with the current price, as the forward P/E is significantly lower than the historical average. The price-to-book ratio is 1.41, which indicates that the market is pricing the company at a moderate premium over its net book value, suggesting some level of intangible asset valuation or growth expectation attached to the stock. Alternative valuation metrics include a price-to-sales ratio of 1.41 and an EV/EBITDA of 9.19, figures that suggest the company is valued based on revenue multiples and enterprise value relative to earnings power, offering a different perspective than the high P/E multiple. The stock has exhibited volatility within a 52-week trading range defined by a high of $27.64 and a low of $18.80. Without a specific current share price provided in the facts, the relative positioning cannot be calculated as a percentage of the range, but the spread between the high and low demonstrates the stock's price movement over the past year. The beta value is 0.20, which means the stock's price volatility is significantly lower than the broader market, moving with much less intensity than the overall index.
Growth & Income
Revenue growth for the trailing twelve months was 5.1%, while earnings growth was -88.4%, indicating that earnings are growing much slower than revenue due to the sharp decline in profitability. This divergence implies that top-line expansion is not yet translating into bottom-line gains, likely due to high fixed costs or one-time expenses impacting the net income figure. As a non-dividend payer, Pacira BioSciences, Inc. has a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings back into growth initiatives, research, and operational expansion rather than distributing cash to shareholders. The overall growth and income profile is characterized by steady revenue expansion coupled with a complete reinvestment strategy, foregoing current income generation to potentially fuel future profitability and market share acquisition in the specialty drug sector.